Evotec CSO: BMS Opt In On CNS Compound ‘Augurs Well’ For Discovery Pact
Brings Bristol Myers Additional Program Rights In Neurodegenerative Diseases.
Executive Summary
Further promising compounds will be explored after Bristol Myers Squibb exercised its option to enter an exclusive license for Evotec’s investigational EVT8683, generated by the German group’s iPSC platform as a potential treatment for neurodegenerative conditions.
You may also be interested in...
Deal Watch: Vertex Calls On CRISPR Yet Again, Now To Collaborate On Type 1 Diabetes
Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.
Deal Watch: Novo Nordisk Links With Flagship To Create Cardiometabolic, Rare Disease Portfolio
The Danish diabetes titan teams with Moderna’s founder on cardiometabolic R&D. Troubled cell therapy biotech Bone Therapeutics negotiates reverse merger with Medsenic.
Finance Watch: Evotec, LianBio, IO Biotech Launch IPOs, Bringing US Total To 101
Public Company Edition: Blade will merge with a special purpose acquisition corporation to go public, Bluebird spins out 2seventy with $442m in cash and Compass raises $125m in a move to the Nasdaq.